Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Ovary removal during hysterectomy protects against future risk of ovarian cancer

While ovary removal during hysterectomy protects against future risk of ovarian cancer, the decision to conserve the ovaries and the hormones they produce may have advantages for preventing heart disease, hip fracture, sexual dysfunction, and cognitive decline.

26 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Cancer prehabilitation has potential to reduce problems, improve physical and mental health outcomes

For patients with cancer, "prehabilitation"— interventions given between the time of diagnosis and the start of treatment—has the potential to reduce complications from treatments and improve physical and mental health outcomes, according to a report in the August American Journal of Physical Medicine & Rehabilitation.

19 Jul 2013

Both milky spots and fat cells in omentum promote ovarian cancer metastases

Cancer researchers have wondered why ovarian cancer cells are so attracted to the abdominal cavity, especially the omentum, with the hope that such an understanding could lead to better disease management or even prevention.

18 Jul 2013

Women who survive cancer have severe menopausal hot flashes

Women who survive cancer have more frequent, severe, and troubling hot flashes than other women with menopausal symptoms, according to a study published online today in Menopause, the journal of The North American Menopause Society (NAMS).

17 Jul 2013

Researchers discover that APOBEC3B is important cancer mutagen

Researchers at the University of Minnesota have discovered that a human antiviral enzyme causes DNA mutations that lead to several forms of cancer.

15 Jul 2013

Innovative vaccine could offer hope to patients with advanced ovarian cancer

Loyola University Medical Center is conducting a clinical trial of an innovative vaccine that could offer hope to patients with advanced ovarian cancer.

10 Jul 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

COTI-2 is a computer-designed small molecule that was discovered by our artificial intelligence drug discovery platform called CHEMSAS.

8 Jul 2013

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Precision Therapeutics, a leading life-science company dedicated to the improvement of patient outcomes in personalized medicine, today announced findings that support the ChemoFx chemoresponse assay as a tool to aid in the identification of platinum resistance in primary ovarian cancer, according to a presentation at the Annual Meeting of The Western Association of Gynecologic Oncologists June 26-29, in Seattle, Washington.

8 Jul 2013

Mothers commonly talk to children about genetic test even it they test positive for gene mutation

Mothers commonly talk to their children about genetic test results even if they test positive for a BRCA1 or BRCA2 gene mutation, which sharply increases a woman's risk of developing breast and ovarian cancer.

3 Jul 2013

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma Inc. announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer.

2 Jul 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

MPIIB researchers show that Chlamydia infections can cause mutations in host DNA

Chlamydia trachomatis is a human pathogen that is the leading cause of bacterial sexually transmitted disease worldwide with more than 90 million new cases of genital infections occurring each year. About 70 percent of women infected with Chlamydia remain asymptomatic and these bacteria can establish chronic infections for months, or even years. Even when it causes no symptoms, Chlamydia can damage a woman's reproductive organs. In addition, standard antibacterial drugs are proving increasingly ineffective in complete eradication, as Chlamydia goes in to persistent mode, leading to asymptomatic chronic infection.

21 Jun 2013

Study describes molecular bases of resistance to new chemotherapeutic agent in familial breast and ovarian cancers

It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2.

19 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

Pathway Genomics to provide genetic testing for BRCA gene linked to breast, ovarian cancers

Pathway Genomics led the evening news Friday with an announcement that it could begin offering affordable access to genetic testing for the BRCA gene linked to breast and ovarian cancers in the wake of a Supreme Court ruling that eliminated another company's monopoly on the test.

15 Jun 2013

Supreme Court invalidates patents held by Myriad Genetics

The College of American Pathologists applauds today's unanimous Supreme Court decision invalidating the patents held by Myriad Genetics on the BRCA1 and BRCA2 genes. It is a victory for patients and for science.

14 Jun 2013

Ambry Genetics introduces BRCA1 and BRCA2 analysis

Ambry Genetics announced today the launch of BRCA1 and BRCA2 analysis as part of their comprehensive cancer-testing menu. Two genes will be offered as a stand alone test comprising of full gene sequencing and deletion/duplication analyses in addition to being incorporated as part of multiple hereditary cancer panels that test cancer susceptibility genes using next-generation sequencing technology.

14 Jun 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Ovary removal during hysterectomy protects against future risk of ovarian cancer

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Cancer prehabilitation has potential to reduce problems, improve physical and mental health outcomes

Both milky spots and fat cells in omentum promote ovarian cancer metastases

Women who survive cancer have severe menopausal hot flashes

Researchers discover that APOBEC3B is important cancer mutagen

Innovative vaccine could offer hope to patients with advanced ovarian cancer

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Mothers commonly talk to children about genetic test even it they test positive for gene mutation

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

MPIIB researchers show that Chlamydia infections can cause mutations in host DNA

Study describes molecular bases of resistance to new chemotherapeutic agent in familial breast and ovarian cancers

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Pathway Genomics to provide genetic testing for BRCA gene linked to breast, ovarian cancers

Supreme Court invalidates patents held by Myriad Genetics

Ambry Genetics introduces BRCA1 and BRCA2 analysis

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in